Good ideas and conversation. No ads, no tracking. Login or Take a Tour!
Some of you may recall me posting about a Covid project I was working on in the spring when the situation was pretty bleak here in Detroit. I was manufacturing an experimental drug that I've been developing mainly to stem neurodegeneration after brain injuries. However, I had an idea that because it targets a very specific immune system function called "complement" that it might be helpful for very sick covid patients. When FDA didn't let us go forward, I was a little annoyed but unsurprised. However, it now looks as if overactive complement is a driving force behind severe disease, so now I'm pissed off all over again. Oh well, the more we learn, hopefully the better chance people have of a good outcome---shouldn't be so prideful.